Meetings & events

Meeting Reports

Dr Matteo Bovolenta presents to Biomarker Industry Representatives

Dr Matteo Bovolenta (UNIFE) attended and presented at the Companion Diagnostics Summit Europe in Frankfurt on 22-24 March 2011. His presentation was to cover:

• Introduction and brief overview of the BIO-NMD project
• Overall omics strategies for biomarker discovery
• News and views on biomarkers in neuromuscular disorders

Matteo began by explaining why biomarkers are needed in neuromuscular disorders. He gave the rationale for the BIO-NMD project, showing the work package organization and the role of each partner within the FP7 EU funded project. He outlined the timeline of the project and specifically explained WP2 and the preliminary data of the partners' RNAseq experiments on COLVI patients treated with Cyclosporin A.

In the last part of the presentation, Matteo discussed the data from recent papers on exploratory cell biomarkers in DMD and COLVI disorders and exploratory transcriptomic biomarkers in DMD.

Matteo can be contacted at

 

Kick Off Meeting (KOM) 28-30th Jan 2010

The BIO-NMD EU project (FP7, HEALTH-2009-2.4.4-1: Rare neurological diseases) “Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders” was officially launched on the 28th-30th of January 2010, at the kick-off meeting (KOM) in Ferrara, Italy.

The consortium is led by the University of Ferrara’s Prof. Alessandra Ferlini and involves 12 partner institutions:
University of Ferrara, Italy; University of Leiden, The Netherlands; University of Newcastle upon Tyne, UK; University of Padova, Italy; Inst. of Child Health, University College London, UK; Tor Vergata University of Rome, Italy; National Health and Medical Research Institute, France; University of Milan, Italy; Royal Institute of Technology, Stockholm, Sweden; Ariadne Genomics Inc., Appliedbiosystems; P2R, France

BIO-NMD is funded until December 2012 and will focus on identifying biomarkers in the collagen VI myopathies and Duchenne muscular dystrophy.

45 participants from Italy, the United Kingdom, the Netherlands, France, Germany, Sweden and United States attended the KOM. Participants included BIO-NMD partners and members of the BIO-NMD committees including the scientific advisory board (SAB), patient association committee (PAC) and project ethics board (PEB). Additionally, a number of  parents' associations and granting agencies namely, Telethon Italy, Association Francaise pour le Myopathie, Duchenne Parent Project, Muscular Dystrophy Campaign were invited to attend as well as representatives of the TREAT-NMD EU Network of Excellence and the EU NMD-CHIP project.
 

 




FP7 & EU flag